Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2004;43:680-685
Published online before print January 19, 2004, doi: 10.1161/01.HYP.0000115924.94236.91
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
43/3/680    most recent
01.HYP.0000115924.94236.91v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bove, C. M.
Right arrow Articles by Kramer, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bove, C. M.
Right arrow Articles by Kramer, C. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Heart Attack
Hazardous Substances DB
*NITRIC OXIDE
Related Collections
Right arrow Congestive
Right arrow ACE/Angiotension receptors
Right arrow Animal models of human disease
Right arrow CT and MRI
Right arrow Acute myocardial infarction

(Hypertension. 2004;43:680.)
© 2004 American Heart Association, Inc.


Scientific Contributions

Nitric Oxide Mediates Benefits of Angiotensin II Type 2 Receptor Overexpression During Post-Infarct Remodeling

Christina M. Bove; Zequan Yang; Wesley D. Gilson; Frederick H. Epstein; Brent A. French; Stuart S. Berr; Sanford P. Bishop; Hiroaki Matsubara; Robert M. Carey; Christopher M. Kramer

From Departments of Medicine (C.M.B., R.M.C., C.M.K.), Radiology (F.H.E., B.A.F., S.S.B., C.M.K.), and Biomedical Engineering (Z.Y., W.D.G., F.H.E., B.A.F., S.S.B.), University of Virginia, Charlottesville; Department of Pathology (S.P.B.), University of Alabama, Birmingham; and Department of Cardiovascular Medicine (H.M.), Kyoto Prefectural University School of Medicine, Kyoto, Japan.

Correspondence to Dr Christopher M. Kramer, University of Virginia Health System, Departments of Medicine and Radiology, Lee Street, Box 800170, Charlottesville, VA 22908. E-mail ckramer{at}virginia.edu

We hypothesized that nitric oxide (NO) mediates the benefits of cardiac angiotensin II type 2 (AT2-R) overexpression during postmyocardial infarction (post-MI) remodeling. Eleven wild-type (WT) C57BL/6 mice and 28 transgenic (TG) mice with AT2-R overexpression were studied by cardiac magnetic resonance imaging (CMR) at baseline and days 1 and 28 post-MI induced by left anterior descending artery occlusion and reperfusion. Sixteen TG mice were treated from day 1 through 28 post-MI with the NO synthase inhibitor NG-nitro-L-arginine methyl ester in drinking water at 1 mg/mL (TG-Rx). Left ventricular mass index (LVMI), end-diastolic volume index (EDVI) and end-systolic volume index (ESVI), wall thickness, percent thickening, and ejection fraction (EF) were measured. Infarct size on day 1 was assessed by post-contrast CMR. Interstitial collagen was quantified in noninfarcted regions. At baseline, heart rate (HR), blood pressure (BP), LVMI, EDVI, and ESVI were similar between groups, as were infarct size and weekly post-MI HR and systolic BP. By day 28 post-MI, EDVI and ESVI were similar in WT and TG-Rx, but significantly lower in TG (ESVI: 1.41±0.18 µL/g versus 2.53±0.14 µL/g in WT; 2.17±0.14 µL/g in TG-Rx; P<0.008 for both). At day 28, EF was higher in TG (46.3%±2.9%) compared with WT and TG-Rx (32.7±2.3% and 33.7±2.3, respectively; P<0.003 for both). Wall thickening at day 28 post-MI was greater in the base and mid-LV in TG than WT and TG-Rx. Noninfarcted region interstitial collagen was similar between groups. Thus, the NO pathway may mediate much of the benefits of cardiac AT2-R overexpression during post-MI remodeling.


Key Words: angiotensin • MRI • myocardial infarction • remodeling • nitric oxide • receptors • imaging




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
X. Yan, A. J. T. Schuldt, R. L. Price, I. Amende, F.-F. Liu, K. Okoshi, K. K. L. Ho, A. J. Pope, T. K. Borg, B. H. Lorell, et al.
Pressure overload-induced hypertrophy in transgenic mice selectively overexpressing AT2 receptors in ventricular myocytes
Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1274 - H1281.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
D. C. Isbell, S. Voros, Z. Yang, J. M. DiMaria, S. S. Berr, B. A. French, F. H. Epstein, S. P. Bishop, H. Wang, R. J. Roy, et al.
Interaction between bradykinin subtype 2 and angiotensin II type 2 receptors during post-MI left ventricular remodeling
Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3372 - H3378.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Voros, Z. Yang, C. M. Bove, W. D. Gilson, F. H. Epstein, B. A. French, S. S. Berr, S. P. Bishop, M. R. Conaway, H. Matsubara, et al.
Interaction between AT1 and AT2 receptors during postinfarction left ventricular remodeling
Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1004 - H1010.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. M. Carey
Cardiovascular and Renal Regulation by the Angiotensin Type 2 Receptor: The AT2 Receptor Comes of Age
Hypertension, May 1, 2005; 45(5): 840 - 844.
[Full Text] [PDF]